Tacrolimus liposomal - Lipella Pharmaceuticals

Drug Profile

Tacrolimus liposomal - Lipella Pharmaceuticals

Alternative Names: Intravesical tacrolimus; Liposomal tacrolimus; LP-10

Latest Information Update: 26 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipella Pharmaceuticals
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cystitis

Most Recent Events

  • 02 May 2017 Lipella Pharmaceuticals plans a phase II trial for Cystitis (Second-line therapy or greater) (Intravesicular) (NCT03129126)
  • 06 May 2016 Preclinical data presented at the Annual Meeting of the American Urological Association (AUA-2016)
  • 13 May 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top